HYDERABAD, India Indian generic drug maker Dr. Reddy’s Labs has launched a version of an asthma drug for the U.S. market, the company said.
Dr. Reddy’s announced the launch of zafirlukast tablets in the 10-mg and 20-mg strengths. The drug is a version of AstraZeneca’s Accolate, which had sales of $50 million during the 12-month period ended in August, according to IMS Health.
The launch follows a decision in the U.S. District Court of New Jersey determining that the Dr. Reddy’s launch of the drug does not infringe on AstraZeneca’s patents. The Food and Drug Administration approved the drug last Thursday.